FTO and neoplasm: Recently, peripheral blood m6A modifier seems to be a potential noninvasive biomarker for the detection and diagnosis of NSCLC, and down-regulating FTO and ALKBH5 in NSCLC had a great connection with tumor stage and metastasis 158.